AZD4547 clinical trials
Also written AZD4547 and ABSK091.
How each study uses AZD4547 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the AZD4547 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2014 (4)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 9
AstraZeneca (5) · Abbisko Therapeutics Co, Ltd (3) · National Cancer Institute (NCI) (2) · UNICANCER (2) · University of Birmingham (1) · ECOG-ACRIN Cancer Research Group (1) · SWOG Cancer Research Network (1) · Assistance Publique - Hôpitaux de Paris (1)
Often tested with
Tested in the same studies.
Capivasertib (4) · Vistusertib (3) · Durvalumab (3) · Docetaxel (3) · Adavosertib (2) · Crizotinib (2) · Osimertinib (2) · Palbociclib (2)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses AZD4547 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUCRecruitingPhase 2Abbisko Therapeutics Co, LtdNCT05775874Written as AZD4547
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Fexagratinib
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingPhase 1AstraZenecaNCT02546661Written as AZD4547
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedPhase 2University of BirminghamNCT02664935Written as AZD4547
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingPhase 2UNICANCERNCT02299999Written as AZD4547
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedPhase 2UNICANCERNCT02117167Written as AZD4547
- Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung CancerCompletedPhase 1/2ECOG-ACRIN Cancer Research GroupNCT01824901Written as AZD4547
- ABSK091 Food Effect Study in Healthy SubjectsCompletedPhase 1Abbisko Therapeutics Co, LtdNCT05533788Written as ABSK091 tablet
- A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547Status unknownPhase 1/2Abbisko Therapeutics Co, LtdNCT05086666Written as AZD4547
- Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)CompletedPhase 2National Cancer Institute (NCI)NCT04439240Written as FGFR Inhibitor AZD4547
- Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedPhase 2/3SWOG Cancer Research NetworkNCT02965378Written as FGFR Inhibitor AZD4547
- Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion"CompletedPhase 1/2Assistance Publique - Hôpitaux de ParisNCT02824133Written as AZD4547
- Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced TumoursTerminatedPhase 1AstraZenecaNCT00979134Written as AZD4547
- Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal CancerTerminatedPhase 2AstraZenecaNCT01457846Written as AZD4547
- Study to Assess Safety and Tolerability of AZD4547 in Japanese PatientCompletedPhase 1AstraZenecaNCT01213160Written as AZD4547
- Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer PatientsCompletedPhase 1/2AstraZenecaNCT01202591Written as AZD4547
- Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified TumoursStatus unknownPhase 2Royal Marsden NHS Foundation TrustNCT01795768Written as AZD 4547